Mr. Muiris O'Connor:

Yes. The crucial issue of Irish citizens in the North will be centre stage in the next phase of negotiations. There is some reassuring language around no diminution of their rights in the grand European context. That is hopeful.

Before I pass over to Mr. Smyth, I will address Deputy O'Connell's point. Shared packaging between the UK, Ireland and Malta has served us well. We share the English language. Shared packaging presumably gives us good bang for our buck and reduces prices. The Health Products Regulatory Authority, HPRA, is working closely and proactively with other European countries on dual-language packaging so that we can replicate the kind of arrangement that we have with the UK with another large market, for example, France or the Netherlands. The impact on pricing, currency inflation, the tariff that might apply in a collapse, the tariff that might apply in benign circumstances and all other scenarios are being considered under the procurement strand.

The quantum of medicines that are produced in and come directly from the UK is less than I had presumed at the outset, but we need to examine what drugs are involved as well as potential alternative markets.